Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Pharmala Biotech Holdings Inc C.MDMA

Alternate Symbol(s):  MDXXF

PharmAla Biotech Holdings Inc. is a Canada-based biotechnology company. The Company is focused on the development, manufacture and sales of methylenedioxy methamphetamine (MDMA) and methylenedioxy phenethylamines (MDXX) class molecules in service to the burgeoning clinical research community and growing commercial use cases in select jurisdictions. The Company has three primary business lines: the manufacture of MDMA and MDXX class molecules for sale to clinical researchers in both the commercial and academic sphere, the research and development of novel MDXX class compounds which offer unique benefits above and beyond known substances, and the development of novel delivery mechanisms for MDMA and MDXX class compounds. Its research and development unit has completed proof-of-concept research into several IP families, including ALA-002, its lead drug candidate. It works with laboratories across Canada to develop novel processes for the supply of LaNeo MDMA and other MDXX substances.


CSE:MDMA - Post by User

Comment by Firepokeron Apr 07, 2024 12:05pm
66 Views
Post# 35975551

RE:Insurance coverage for therapy

RE:Insurance coverage for therapy Alberta Blue Cross has already approved insurance coverage for psychedelic assisted therapy in 2002 for certain patients...so when FDA approval is given in August for the others ...and Blue Cross has already opened the "insurance coverage" gateway door...let's hope all falls into place smoothly for everyone, not just first responders.


"We welcome Alberta Blue Cross as the first major provincial insurer to cover Psychedelic-Assisted Therapy in all of its forms,” said Philippe Lucas, PhD, President of SABI Mind, a psychedelic clinic group based in Alberta. “Psychedelic treatments such as ketamine-assisted psychotherapy are proving to be safe and cost-effective interventions for patients with poor treatment success with traditional mental health therapies, but they remain out of reach to many that could benefit. We hope the leadership shown by Alberta Blue Cross is the starting point to increased access for all patients all across Canada that could benefit from psychedelic-assisted therapies."
<< Previous
Bullboard Posts
Next >>